论文部分内容阅读
对６２１名单采浆ＨＢｓＡｇ阴性献血员及３５４名ＨＢｓＡｇ阴性非献血者和１２４名单采浆ＨＢｓＡｇ阳性献血员及１２４名ＨＢｓＡｇ阳性非献血者进行调查，结果－ＨＣＶ阳性率分别为８４．２２％（５２３／６２１）、０．８５％（３／３５４）、４１．９４％（５２／１２４）、１．６１％（２／１２４），肝炎现患率分别为３４．９４％（２１７／６２１）、１．９８％（７／３５４）、１８．５５％（２３／１２４）、４．８４％（６／１２４）。调查结果表明，ＨＣＶ的感染和丙型肝炎的流行主要发生在单采浆还输血球献血员中。提示在单采浆还输血球过程中应注意避免医源性交叉感染以及对所有献血员、输成分血和用于制备注射用制品的血浆检测抗－ＨＣＶ是非常必要的。在血浆制品的制备工艺中能否将ＨＣＶ全部灭活是一个十分值得重视的问题。
A total of 621 single plasmapheresis HBsAg negative donors and 354 HBsAg negative non-donors and 124 single plasmapheresis HBsAg positive donors and 124 HBsAg positive non-donors were investigated. The positive rates of HCV-HCV were 84.22% (523 /621),0.85%(3/354),41.94%(52/124),1.61%(2/124). The prevalence rates of hepatitis were 34.94% (217/621), 1 .98% (7/354), 18.55% (23/124), 4.84% (6/124). The results of the survey indicate that the prevalence of HCV infection and hepatitis C occurs predominantly in apheresis blood transfusion blood donors. It is suggested that it is necessary to avoid iatrogenic cross-infection and detect anti-HCV for all blood donors, blood transfusions and plasma used for preparation of injectable products during the apheresis and transfusions. Whether the inactivation of HCV can be completely inactivated during the preparation of plasma products is a very important issue.